Skip to main content
You are the owner of this article.
You have permission to edit this article.
Cancer drug startup raises $625,000 in capital

Cancer drug startup raises $625,000 in capital

Dr. William Hawkins of Washington University

Dr. William Hawkins, professor of surgery at Washington University and co-founder of Accuronix Therapeutics.

BioGenerator and the state-funded Missouri Technology Corp. have invested in a cancer-drug startup that's based on Washington University research.

The startup, Accuronix Therapeutics, raised a total of $625,000, with BioGenerator as the lead investor. Accuronix is developing drugs for difficult-to-treat forms of cancer, starting with pancreatic cancer.

Its technology is based on research by Dr. William Hawkins, professor of surgery at Washington University, and Dr. Robert Mach of the University of Pennsylvania. Accuronix's chief executive is Dennis Schafer, a senior entrepreneur in residence at BioGenerator and veteran of a dozen biotech startups.

Accuronix has been based at BioGenerator's lab space in the Central West End, and in 2014 it received a small amount of money from BioGenerator's concept fund.

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Get up-to-the-minute news sent straight to your device.



Blues News

Breaking News

Cardinals News

Daily 6

National Breaking News